After topping the Street's expectations with its Q3 earnings, Cipla announced plans to launch two key drugs in FY26—the respiratory drug Advair and the oncology drug Abraxane. Umang Vohra ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback